OncoCyte Co. (NASDAQ:OCX) Major Shareholder Patrick W. Smith Acquires 90,219 Shares

OncoCyte Co. (NASDAQ:OCX) major shareholder Patrick W. Smith bought 90,219 shares of OncoCyte stock in a transaction that occurred on Thursday, December 26th. The shares were bought at an average cost of $2.13 per share, with a total value of $192,166.47. Following the acquisition, the insider now directly owns 1,773,903 shares in the company, valued at $3,778,413.39. This trade represents a 5.36 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

OncoCyte Stock Down 2.9 %

Shares of OCX opened at $2.38 on Wednesday. OncoCyte Co. has a 12 month low of $1.97 and a 12 month high of $3.82. The firm’s 50 day moving average is $2.59 and its 200-day moving average is $2.89.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). The company had revenue of $0.12 million for the quarter. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. During the same quarter in the previous year, the business posted ($0.57) EPS. As a group, research analysts anticipate that OncoCyte Co. will post -2.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in OncoCyte stock. Geode Capital Management LLC raised its position in shares of OncoCyte Co. (NASDAQ:OCX) by 12.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,980 shares of the company’s stock after purchasing an additional 11,289 shares during the period. Geode Capital Management LLC owned approximately 0.62% of OncoCyte worth $296,000 at the end of the most recent reporting period. 55.35% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

OCX has been the subject of a number of research analyst reports. StockNews.com began coverage on OncoCyte in a report on Wednesday. They set a “sell” rating for the company. Needham & Company LLC restated a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a research note on Wednesday, November 13th.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.